Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

MABN784 Anti-FMR1polyG Antibody, clone 2J7

MABN784
100 μg  
Purchase on Sigma-Aldrich

Speciální nabídky

Přehled

Replacement Information

Speciální nabídky

Tabulka spec. kláve

Species ReactivityKey ApplicationsHostFormatAntibody Type
HWB, IHC, ICCMPurifiedMonoclonal Antibody
Description
Catalogue NumberMABN784
DescriptionAnti-FMR1polyG Antibody, clone 2J7
Alternate Names
  • Fragile X mental retardation protein 1 RANT fusion
  • FMR1polyG
  • FMRP RANT fusion
  • FMR-1 RANT fusion
Background InformationFragile X-associated Tremor/Ataxia syndrome (FXTAS) is a neurodegenerative disorder caused by an elevated CGG-repeat expansions (55-200) in the 5′ UTR of the fragile-X mental retardation 1 gene FMR1 (also known as FRAXA, POF1; Gene ID 2332) on the X-chromosome. The CGG repeat expansion in FXTAS triggers repeat-associated non-ATG-initiated translation (RAN or RANT), also known as repeat-associated non-AUG-initiated translation, within the 5’UTR of FMR1 mRNA, resulting in the production of fusion proteins (FMR1polyG) that contain N-terminal polyglycine fused to either C-terminal FMR1 in-frame sequence or one of two FMR1 frame-shift sequences. Immunohistochemical analysis of FXTAS brain tissues reveals FMR1polyG-positive aggregates that closely resemble neuronal intranuclear inclusions seen in polyglutamine diseases and other protein-mediated neurodegenerative disorders. Much larger expansions of the same repeat cause fragile X syndrome (FRAX), the most common inherited form of mental retardation, by silencing FMR1 transcription.
References
Product Information
FormatPurified
PresentationPurified mouse monoclonal IgG2bκ antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Quality LevelMQ100
Applications
Key Applications
  • Western Blotting
  • Immunohistochemistry
  • Immunocytochemistry
Application NotesImmunohistochemistry Analysis: A representative lot detected FMR1polyG immunoreactivity in paraffin-embedded brain tissue sections from Fragile X-associated Tremor/Ataxia syndrome (FXTAS) patients, but not in brain tissues from non-FXTAS individuals (Todd, P.K., et al. (2013). Neuron. 78(3):440-455).
Immunohistochemistry Analysis: A representative lot detected both ubiquitinated inclusions-associated and non-inclusions-associated FMR1polyG immunoreactivity by dual fluorescent immunohistochemistry using paraffin-embedded brain tissue sections from Fragile X-associated Tremor/Ataxia syndrome (FXTAS) patients (Todd, P.K., et al. (2013). Neuron. 78(3):440-455).
Western Blotting Analysis: A representative lot detected recombinant FMRpolyG GST fusion constructs, while only one immunoreactive band (~15 kDa) could be detected in Fragile X-associated Tremor/Ataxia syndrome (FXTAS) patients brain lysates due to extended aggregation of FMR1polyG (Todd, P.K., et al. (2013). Neuron. 78(3):440-455).
Immunocytochemistry Analysis: A representative lot detected exogenously expressed FLAG-FMR1polyG constructs by fluorescent immunocytochemistry (Todd, P.K., et al. (2013). Neuron. 78(3):440-455).
Biological Information
ImmunogenOvalbumin-conjugated linear peptide corresponding to a sequence from the C-terminal region of FMR1polyG.
EpitopeC-terminal region.
Clone2J7
ConcentrationPlease refer to lot specific datasheet.
HostMouse
SpecificityThis monoclonal antibody does not detect the Fragile X mental retardation protein 1 sequences reported by UniProt (Q06787-1 through Q06787-9). It detects one of the two possible types of FMR1 frame-shift sequences with N-terminal polyG fusion found in Fragile X-associated Tremor/Ataxia syndrome (FXTAS) patients due to CGG repeats expansion (55-200 repeats) in the 5’UTR of the FMR1 gene. Due to the extended aggregation of the pathological forms of FMR1polyG, the detection of FMR1polyG in patient samples by Western blotting is not recommended.
IsotypeIgG2bκ
Species Reactivity
  • Human
Antibody TypeMonoclonal Antibody
Gene Symbol
  • FMR1
  • FRAXA
  • POF1
Purification MethodProtein G Purified
UniProt Number
Molecular WeightVariable, depending on the sizes of the FMR1polyG fusions and aggregates.
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Quality AssuranceEvaluated by Western Blotting in COS GFP-FMRpolyG cells.

Western Blotting Analysis: 1.0 µg/mL of this antibody detected an exogenously expressed FMR1polyG GFP fusion construct in transfected COS cells.
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsStable for 1 year at 2-8°C from date of receipt.
Packaging Information
Material Size100 μg
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Katalogové číslo GTIN
MABN784 04055977311846

Documentation

Anti-FMR1polyG Antibody, clone 2J7 MSDS

Title

Safety Data Sheet (SDS) 

Anti-FMR1polyG Antibody, clone 2J7 Certificates of Analysis

TitleLot Number
Anti-FMR1polyG, clone 2J7 - 3386858 3386858
Anti-FMR1polyG, clone 2J7 - 3776234 3776234
Anti-FMR1polyG, clone 2J7 -Q2635125 Q2635125
Anti-FMR1polyG, clone 2J7 Monoclonal Antibody 3030517
Anti-FMR1polyG, clone 2J7 Monoclonal Antibody 2925948
Anti-FMR1polyG, clone 2J7 Monoclonal Antibody 2956743

References

Reference overviewPub Med ID
CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome.
Todd, PK; Oh, SY; Krans, A; He, F; Sellier, C; Frazer, M; Renoux, AJ; Chen, KC; Scaglione, KM; Basrur, V; Elenitoba-Johnson, K; Vonsattel, JP; Louis, ED; Sutton, MA; Taylor, JP; Mills, RE; Charlet-Berguerand, N; Paulson, HL
Neuron  78  440-55  2013

Zobrazit abstrakt
23602499 23602499

Brochure

Title
Neuroscience Solutions for productive research